Warsaw 2013 Programme Registration Exhibition Hotels Virtual Exhibition Warsaw Satellite Meetings Visa Information

Bevacizumab augmented trabeculectomy

Poster Details

First Author: A.El Habbak EGYPT

Co Author(s):    T. Soliman   M. Abdrabbo           

Abstract Details


To assess the outcomes of Trabeculectomy with intraoperative subconjunctival Bevacizumab in POAG and CACG .


: Prospective , randomized comparative study.


32 eyes of 32 patients with uncontrolled glaucoma were included in this study. 16 eyes ( Group 1) underwent Trabeculectomy with MMC (0.02% for 3 minutes). 16 eyes ( Group 2) underwent Trabeculectomy with MMC (0.02% for 3 minutes) plus Bevacizumab (1.25 mg / 0.05 ml at the same time ). The outcomes measures were visual acuity, IOP, bleb morphology and complications.


The mean preoprative IOP was 56.2±2.4 mmHg in Group 1 and 29.3±5.6 mmHg in Group 2 . The mean postoperative IOP was 11.2±2.9 mmHg in Group 1 and 10.6±2.4 mmHg in Group 2 after 6 months.


Bevacizumab improved the outcome of filtration surgery . It may be a useful adjunct in reducing bleb failure after Trabeculectomy.

Financial Disclosure:


Back to previous